| Literature DB >> 30300771 |
Yohann Loriot1, Stéphane Supiot2, Jean-Baptiste Beauval3, Friederike Schlürmann4, Gilles Pasticier5, Paul Sargos6, Philippe Barthélémy7, Géraldine Pignot8, Denis Maillet9, Sébastien Vincendeau10, Emmanuel Gross11, Guillaume Ploussard12, Marc-Olivier Timsit13, Delphine Borchiellini14.
Abstract
Management of non metastatic castrate resistant prostate cancer is challenging for clinicians due to the heterogeneity of the disease and to the scarce clinical data available in this setting. Recent results obtained with the new generation hormone therapies (NGHT) apalutamide and enzalutamide bring a new perspective for the treatment strategy. The authors present here a systematic review of the treatment options.Entities:
Keywords: Castration-resistant; Hormone therapies; Non-metastatic; Prostate cancer; nmCRPC
Mesh：
Substances：
Year: 2018 PMID： 30300771 DOI： 10.1016/j.ctrv.2018.09.006
Source DB: PubMed Journal: Cancer Treat Rev ISSN： 0305-7372 Impact factor: 12.111